全文获取类型
收费全文 | 71405篇 |
免费 | 4389篇 |
国内免费 | 270篇 |
专业分类
耳鼻咽喉 | 1112篇 |
儿科学 | 2026篇 |
妇产科学 | 1326篇 |
基础医学 | 7925篇 |
口腔科学 | 1454篇 |
临床医学 | 7025篇 |
内科学 | 14822篇 |
皮肤病学 | 1113篇 |
神经病学 | 6910篇 |
特种医学 | 2488篇 |
外国民族医学 | 5篇 |
外科学 | 12374篇 |
综合类 | 853篇 |
一般理论 | 94篇 |
预防医学 | 5949篇 |
眼科学 | 1382篇 |
药学 | 4549篇 |
中国医学 | 111篇 |
肿瘤学 | 4546篇 |
出版年
2023年 | 394篇 |
2022年 | 647篇 |
2021年 | 1771篇 |
2020年 | 928篇 |
2019年 | 1550篇 |
2018年 | 1812篇 |
2017年 | 1307篇 |
2016年 | 1338篇 |
2015年 | 1474篇 |
2014年 | 2274篇 |
2013年 | 3204篇 |
2012年 | 4852篇 |
2011年 | 5033篇 |
2010年 | 2760篇 |
2009年 | 2450篇 |
2008年 | 4451篇 |
2007年 | 4713篇 |
2006年 | 4569篇 |
2005年 | 4546篇 |
2004年 | 4289篇 |
2003年 | 3950篇 |
2002年 | 3667篇 |
2001年 | 558篇 |
2000年 | 486篇 |
1999年 | 634篇 |
1998年 | 743篇 |
1997年 | 668篇 |
1996年 | 592篇 |
1995年 | 522篇 |
1994年 | 511篇 |
1993年 | 430篇 |
1992年 | 380篇 |
1991年 | 378篇 |
1990年 | 311篇 |
1989年 | 290篇 |
1988年 | 288篇 |
1987年 | 268篇 |
1986年 | 280篇 |
1985年 | 369篇 |
1984年 | 444篇 |
1983年 | 369篇 |
1982年 | 536篇 |
1981年 | 497篇 |
1980年 | 457篇 |
1979年 | 212篇 |
1978年 | 281篇 |
1977年 | 268篇 |
1976年 | 212篇 |
1975年 | 223篇 |
1973年 | 187篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Dr. Andrew G. Bostom M.D. Dr. Anne L. Hume Pharm.D. Dr. Charles B. Eaton M.D. Dr. Joseph P. Laurino Ph.D. Ms. Lisa R. Yanek B.A. Ms. Mary S. Regan B.S. Mr. William H. McQuade M.P.H. Dr. Wendy Y. Craig Ph.D. Ms. Gayle Perrone M.B.A. Dr. Paul F. Jacques Sc.D. 《Pharmacotherapy》1995,15(4):458-464
Study Objective . To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design . Randomized, double-blind, placebo-controlled trial. Setting . Outpatient clinic. Patients . Forty-four patients with documented premature CHD. defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions . Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results . High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dl; p<0.001). Multiple linear regression analysis revealed no significant effect of supplementation on postintervention Lp(a) levels (p=0.39) in a model that included treatment group assignment, and baseline Lp(a) levels. Conclusions . Our findings do not support a clinically important lowering effect of high-dose ascorbate on plasma Lp(a) in patients with premature CHD. 相似文献
32.
Alex Westerband Joseph L. Mills Scott S. Berman Glenn C. Hunter 《Annals of vascular surgery》1997,11(1):14-19
n = 69) normal; Group B (n= 29), abnormal, severe defects; Group C (n= 56), abnormal, mild–moderate defect. RCA detected 32 defects in Group B: 10 internal carotid (ICA), seven endpoint flaps,
two kinks, one dissection; 16 external carotid (ECA), 10 severe endpoint defects and six total occlusion; six common carotid
(CCA), five irregular proximal shelfs, one web. Thirty of 32 defects were successfully repaired as confirmed by normal repeat
RCA studies; one ECA defect was not repaired and the ICA dissection was irreparable. In Group C, 67 mild–moderate defects
were identified, but not corrected. These included <30% stenosis in the ICA (12), ECA (18), CCA (24), and vein patch corrugation
or irregularity (13). For the entire series the postoperative ICA occlusion rate was 2% (3/154), stroke rate 2.6% (4/154),
and a subsequent >50% restenosis rate of 7% (11/154). The yield from routine carotid completion arteriograms was significant,
with 19% of studies identifying a severe defect that required repair. Although the difference in stroke rates and restenosis
between the different groups did not reach statistical significance, patients with normal intraoperative arteriograms initially
or after correction of a significant RCA defect had no early carotid occlusion (p= 0.05, Fisher's exact test) compared to patients with residual RCA defects. All early carotid occlusions occurred in patients
with unrepaired defects. We conclude that RCA is an important method of quality control after CEA and exerts a subtle, but
real, reduction in postoperative complications. 相似文献
33.
Abstract Pericardial tamponade remains a diagnostic challenge
to the clinician especially when the patient is well compensated
hemodynamically. We report an unusual case
who sought medical help 1 month after having been
stabbed in his chest. An investigation revealed a perforation
of the myocardium and a pericardial tamponade.
The patient survived thanks to a large organized clot
that plugged the perforation. The patient was exposed
to increased risk due to delayed onset, recognition, and
therapy of the tamponade. Most reports on this subject
deal with acute pericardial tamponade. Only few cases
of delayed pericardial tamponade have been reported.
A review of the relevant literature and the therapeutic
approaches are discussed. 相似文献
34.
Many degenerative human diseases reflect damage to cells that are not normally repaired or replaced, such as diabetes, Parkinson's disease, hepatic failure and congestive heart failure. Preliminary studies in animals and humans have suggested that these diseases may be treatable by transplantation of healthy cells. Such cells may be obtained by in vitro culture of embryonic stem cells, which are capable of differentiating into many cell types. This review discusses applicative approaches for the derivation, maintenance and safety of human embryonic stem (hES) cells as well as ethical concerns surrounding their possible source for cellular therapy. hES cells offer broad application in cellular therapy; however, this review specifically emphasizes on cardiovascular repair, generation and characterization of hES cell-derived cardiomyocytes, vascular progenitors and differentiation of derivatives. 相似文献
35.
36.
37.
In vivo voltammetry at chronically implanted carbon paste electrodes in unrestrained rats is a particularly useful technique for evaluating neurochemical changes during spontaneous behaviour, or behaviour under experimental control. A 3 peak signal is observed in the striatum; most recently the consensus view has attributed these peaks to ascorbic acid (AA), uric acid (UA) and homovanillic acid (HVA) in ascending order of oxidation potential. We have used a pharmacological approach, combined with in vivo dialysis, to further elucidate the nature of the contributing species. Allopurinol, an inhibitor of xanthine oxidase, and thus of uric acid production, has previously been reported to abolish peak 2. We now report, using dialysis, that it selectively depletes UA in the extracellular fluid (ECF). Pargyline, a monoamine oxidase inhibitor, reduces peak 3 transiently (max. 60%) as expected, however it results in a more sustained reduction in ECF HVA (max. 100%). It also increases peak 1 (max. 75%) and decreases peak 2 (max. 40%), although changes in ECF AA and UA measured by dialysis and HPLC are minimal. Pargyline does however reduce ECF 5-hydroxyindoleacetic acid by 65%. We conclude that, using linear sweep voltammetry at chronically implanted paste electrodes: (a) one or more substances in addition to AA can contribute to peak 1; dopamine can do so in some situations; (b) 5-hydroxyindoleacetic acid, as well as UA, contributes to peak 2; its contribution is about one third that of the latter; and (c) one or more substances in addition to HVA can contribute to peak 3. 3-Methoxytyramine can do so. Since this is another methylated metabolite of dopamine, this does not prevent the use of peak 3 as an index of dopamine metabolism, and may extend its usefulness to situations where monoamine oxidase is inhibited. 相似文献
38.
In the differential clinical diagnosis of mammary neoplasms, adenocarcinoma can safely be excluded only after biopsy and microscopic study.In a series of 177 cases of mammary cancer treated by surgery with x-ray therapy, 30.4 per cent of the patients are alive three years or more after treatment; 18 per cent five years or longer.Only one of every four patients presents herself with a lesion still within the breast. Exclusive of Group I this results in a cure in 86.1 per cent in Group II and 15.4 per cent in Group III. The mortality rate then increases five and one-half times as spread occurs beyond the breast.The results of irradiation therapy for curative purposes in recurrent or metastatic mammary adenocarcinoma are poor.
Stage | Patients Treated | Per Cent Cures |
I | 1 | 100.0 |
II and IIa | 40 | 86.1 |
III and IIIa | 130 | 15.4 |